Induction of antinuclear antibodies in patients with rheumatoid arthritis receiving treatment with human recombinant interferon gamma.
Of six patients with rheumatoid arthritis (RA) treated with human recombinant interferon gamma for two to eight months, three developed antinuclear antibodies (ANAs). This was accompanied by a simultaneous clinical exacerbation of the disease activity. In this study both anti-inflammatory and immunostimulatory effects of human recombinant interferon gamma in patients with RA were observed.
D000328:Adult; D000368:Aged; D000974:Antibodies, Antinuclear / Q000032:analysis*; D001172:Arthritis, Rheumatoid / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007371:Interferon-gamma / Q000627:therapeutic use*; D008875:Middle Aged; D011994:Recombinant Proteins / Q000627:therapeutic use
D000974:Antibodies, Antinuclear; D011994:Recombinant Proteins; D007371:Interferon-gamma